Kineta, Inc. (KANT)
OTCMKTS · Delayed Price · Currency is USD
0.2750
0.00 (0.00%)
Apr 17, 2025, 4:00 PM EDT

Kineta Company Description

Kineta, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies that transform patients’ lives in the United States.

The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug.

KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including non-small cell lung, ovarian, renal cell carcinoma, head and neck, renal cell, and colorectal cancers.

It also developing anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells. It has collaboration and license agreements with MSD International Business GmbH, Genentech, Inc., Merck &Co., Inc., FAIR Therapeutics B.V., and GigaGen, Inc. Kineta, Inc. is headquartered in Mercer Island, Washington.

Kineta, Inc.
Country United States
Industry Biotechnology
Sector Healthcare
Employees 5

Contact Details

Address:
7683 SE27th Street
Mercer Island, Delaware 98040
United States
Phone 206 378 0400
Website kinetabio.com

Stock Details

Ticker Symbol KANT
Exchange OTCMKTS
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
SIC Code 2836

Key Executives

Name Position
Craig W. Philips President and Secretary
Keith A. Baker Chief Financial Officer
Dr. Thierry Guillaudeux Ph.D. Chief Scientific Officer
Gary Gentges Executive Vice President of Corporate Development